Clinical Research Directory

Key Inclusion Criteria: 1. Diagnosis of OHT or POAG of mild to moderate severity as described in the protocol 2. Best-Corrected Visual Acuity (BCVA) of ≥35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent of better than or equal to 20/200) in the study eye on day 1 3. BCVA of ≥55 EDTRS letters (Snellen equivalent of better than or equal to 20/80) in the non-study eye on day 1 4. Phakic or pseudophakic with a posterior chamber intraocular lens that has been implanted ≥3 months prior to Screening Visit 1 5. Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality posterior segment imaging in the study eye Key Exclusion Criteria: Ocular-specific exclusion criteria apply to the Study Eye only, unless otherwise specified. 1. OAG or OHT secondary to pigment dispersion, pseudoexfoliation, trauma, uveitis, neovascularization, a vascular disorder, or steroid use 2. Congenital or traumatic cataract, or visually significant cataract that is likely to require surgical intervention during the study 3. Presence of significant corneal scarring or irregularities that could interfere with reliable IOP measurement 4. Prior incisional or bleb-forming glaucoma surgery, suprachoroidal procedures, Trabecular Meshwork (TM)-stripping Microinvasive Glaucoma Surgery (MIGS), angle-based implants other than iStent or iridectomy/iridotomy as described in the protocol 5. History of Selective Laser Trabeculoplasty (SLT) within 6 months prior to day 1 6. History of transscleral (including micropulse) or endoscopic cyclophotocoagulation within 1 year prior to day 1 Note: Other protocol defined Inclusion/ Exclusion criteria apply